Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Enveric Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ENVB
Nasdaq
8731
https://www.enveric.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Enveric Biosciences Inc
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
- Mar 26th, 2024 11:00 am
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
- Mar 19th, 2024 11:00 am
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
- Mar 12th, 2024 11:00 am
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
- Feb 29th, 2024 12:00 pm
CORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
- Feb 26th, 2024 1:00 pm
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
- Feb 23rd, 2024 1:00 pm
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
- Feb 21st, 2024 1:00 pm
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
- Jan 3rd, 2024 1:00 pm
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
- Dec 29th, 2023 1:52 pm
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
- Dec 28th, 2023 1:00 pm
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
- Dec 27th, 2023 1:00 pm
Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"
- Dec 20th, 2023 1:00 pm
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
- Dec 5th, 2023 1:00 pm
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
- Nov 29th, 2023 1:00 pm
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
- Nov 27th, 2023 1:00 pm
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
- Nov 24th, 2023 1:00 pm
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
- Nov 13th, 2023 9:01 pm
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin
- Oct 31st, 2023 12:00 pm
Enveric Biosciences to Present at the Centurion One 5th Global Summit
- Oct 20th, 2023 12:00 pm
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
- Oct 18th, 2023 12:00 pm
Scroll